IBR733 / Imbioray Bio - LARVOL DELTA

InBio completed nearly RMB 100 million in Series A+ financing, led by Huarui Investment [Google translation] (Sohu.com) - "According to the news from the investment community on January 22, Inbio (Hangzhou) Biopharmaceutical Co., Ltd...recently completed a round of A+ financing of nearly 100 million yuan. This round of financing was led by Huarui Investment, followed by Tailong Investment, Sunzi Technology, Huayi Capital, and Binjiang 5050 Fund. This round of financing is mainly used for the global FIC (first-in-class) universal natural killer cell therapy, that is, the registration clinical projects of innovative biological products such as IBR854, IBR733, IBR822, and IBR900, and to accelerate the launch of a series of original innovative peripheral blood-derived, non-viral vector, non-gene-edited spot universal immune-tamed NK/CAR-raNK and tiNK cell products."

Financing • Hematological Malignancies • Solid Tumor

Study of IBR733 Cell Injection in Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd.

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Yingbairui: IND application for universal off-the-shelf NK cell therapy was accepted by the State Food and Drug Administration [Google translation] (pharnexcloud.com) - "...the IND application for 'IBR733 Cell Injection' of Inbrix (Hangzhou) Biopharmaceutical Co., Ltd. (hereinafter referred to as 'Inbred') was accepted by CDE (acceptance number: CXSL2300643). It is reported that this is the acceptance obtained after Yingbairui resubmitted its IND application using the latest closed automation process....IBR733 injection is a universal off-the-shelf CAR-raNK cell product derived from allogeneic peripheral blood independently developed by Inbri."

New trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology